Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma wi...
March 24 2021 - 6:00PM
(NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian
BioSciences, Inc., a company focused on gene-modified cellular and
immune therapies in infectious diseases and cancer, today announced
that a 36-year old patient with recurrent glioblastoma achieved
complete remission for a period of 15 months. The important
findings were published today, in the peer-reviewed American
Journal of Case Reports
https://www.amjcaserep.com/abstract/indexMobile/idArt/931030.
A complete remission response such as this is
uncommon for this highly aggressive and deadly form of brain
cancer.
In compliance with U.S. Food and Drug
Administration guidance, SRI treated the patient with natural
killer (NK) and dendritic cells (DC) from a relative who had a
partial genetic mismatch. The DCs were loaded with a component of
cytomegalovirus that is known to be present in more than 90 percent
of glioblastomas.
Enochian BioSciences acquired the intellectual
property for an approach that is similar to the one used for this
successful clinical outcome. The novel, proprietary strategy
includes genetic modification of DCs, potentially increasing the
immune response and even more effectively attacking tumors.
Enochian BioSciences is actively developing this enhanced immune
technology, including proof-of-concept in vivo studies of the
potential to clear tumors with a focus on pancreatic cancer. In the
U.S. alone, more than 60,000 persons are diagnosed with pancreatic
cancer, and more than 48,000 die from the disease each year. The
treatment strategy also could be applicable to several solid
tumors.
Dr. Anahid Jewett, a renowned tumor immunologist
and cell and gene therapy investigator at UCLA who has developed a
humanized mouse model of pancreatic cancer, said: “This exciting
clinical finding, as well as many other directions for therapy
which Enochian BioSciences is currently undertaking to develop
related approaches, gives hope for the possibility of effective
treatment for pancreatic cancer and other solid tumors in the
future.”
About Enochian BioSciences,
Inc.Enochian BioSciences, Inc. is a biopharmaceutical
company dedicated to identifying, developing, manufacturing, and
commercializing gene-modified cell therapy. The company’s
gene-modified cell therapy platform can be applied to multiple
indications, including HIV/AIDS, Hepatitis B, and
Oncology.
About Seraph Research
InstituteSeraph Research Institute is a Los Angeles-based
non-profit research institution, which runs basic science,
translational and clinical research in pursuit of cures and
effective treatments for chronic viral infections, cancers, and
genetic disorders.
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Enochian BioSciences’ most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Enochian
BioSciences undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date
hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024